Faculty

The Parkinson's Group Distinguished Faculty

C. Warren Olanow, MD, FRCPC

C. Warren Olanow, MD, FRCPC, Moderator

Disclosure
Consultant: Ceregene, Inc.; Novartis/Orion; Abbot/Solvay; Lundbeck; Teva CNS
Speaker: Teva CNS
Stock Options: Ceregene, Inc.
Stock: Clintrex

Biography

Henry P. and Georgette Goldschmidt Professor and
Chairman Emeritus, Department of Neurology, and
Professor of Neuroscience,
Mount Sinai School of Medicine, New York, NY

Dr. Olanow received his medical degree from the University of Toronto, performed his neurology training at the New York Neurological Institute at Columbia University, and did post-graduate studies in neuroanatomy at Columbia University. He served on the faculties of McGill University, Duke University, and the University of South Florida prior to joining Mount Sinai.

Dr. Olanow has authored more than 300 publications primarily related to Parkinson's Disease and neurodegeneration. He is the past President of the Movement Disorder Society, past Treasurer of the American Neurological Association, and has served on numerous editorial and scientific advisory boards and has lectured at universities and conferences throughout the world.

Matthew B. Stern, MD

Matthew B. Stern, MD, Panelist

Disclosure
Consulting: Adamas Pharmaceuticals, Inc.; Civitas; Medtronic; Merz; Teva CNS

Biography

Director of the Parkinson's Disease and Movement Disorders Center,
Department of Neurology, Parker Family Professor of Neurology,
University of Pennsylvania Health System,
Philadelphia, PA

President of the International Parkinson's Disease and Movement Disorder Society, 2013, Dr. Stern has authored or contributed to 57 pubiications or presentations on Parkinson's Disease and related disorders. Dr. Stern is also a fellow of the American Academy of Neurology, American Neurologic Association, and Philadelphia Neurological Society. He received his medical degree from Duke University School of Medicine, and completed his internship and residency at the Hospital of the University of Pennsylvania.

In addition to serving as institutional investigator for numerous clinical trials, Dr. Stern has been the Principal Investigator or Co-Principal Investigator of many research studies related to Parkinson's disease, and serves on a number of study steering committees, executive committees and safety monitoring boards. Until recently he was codirector of the Parkinson's Disease Research, Education and Clinical Center at the Philadelphia Veteran's Administration Hospital, one of six such centers in the United States. The Center at Penn is one of the largest of its type in the country and has a long track record of achievement in clinical trials and experimental therapeutics. It is also one of the National Parkinson Foundation's Worldwide Centers of Excellence.

Karl Kieburtz, MD, MPH

Karl Kieburtz, MD, MPH

Disclosure
Research Support: National Institutes of Health (NEI, NINDS, NIA, NICHD), the Michael J Fox Foundation, Neurosearch
Consulting: The United States Food and Drug Administration, the Veteran’s Administration and the National Institutes of Health (NINDS); Abbott, Acorda, Aptiv, AstraZeneca, Austpex, Biogen Idec, Biotie, Biovail, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Ceregene, CHDI, Civitas, Clintrex, Cynapsus, Endo, Impax, Intec, Ipsen, Isis, Knopp, Lilly, Lundbeck, LZ Therapeutics, Medivation, Merck, Merz, Neotrope/Elan Pharmaceuticals, Novartis, Orion, Otsuka, Pharm2B, Phytopharm, Roche, Siena Biotech, Sofinnova, Synagile, Synosia, Teva CNS, UCB Pharma, Upsher-Smith, US WorldMeds, Vaccinex, Vectura, Xenoport.
Legal Consulting: Thompson Hine

Biography

Robert J Joynt Professor of Neurology and
Professor of Community and Preventive and Environmental Medicine, and
Director of the Center for Human Experimental Therapeutics,
University of Rochester Medical Center
Rochester, NY

Dr. Kieburtz' primary clinical and research interests are in the treatment of neurodegenerative diseases affecting the basal ganglia, particularly Parkinson's Disease, Huntington's Disease, and HIV-related neurologic disorders. He was one of the founders and has been an active participant in the research activities of the Parkinson Study Group since 1989, and is former Chair of the Executive Committee. He is the principal investigator for the NINDS-sponsored program (NET-PD) of neuroprotective agents for PD and directs the Coordination Center for an NEI-funded consortium in Neuro-opthalmology.

More broadly, Kieburtz is an expert on the design and implementation of large-scale, multi-site clinical studies. He has served on the International Executive Committee of the Movement Disorders Society and as Chair of the FDA Peripheral and Central Nervous System Advisory Committee, and he is an active consultant to both the FDA and the National Institutes of Health.